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The following method of studying the homogeneity of 
pathological biomineral can help to determine the mechanism of 
depositing of calcificates in the walls of vessels, and that will be a 
step forward to finding an effective method of diagnosis and 
treatment of vascular calcification 
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The polymerase chain reaction (PCR) is a technology in 
molecular biology used to amplify a single copy or a few copies of a 
piece of DNA across several orders of magnitude, generating 
thousands to millions of copies of a particular DNA sequence. 
Nowadays scientists widely use PCR method to identify single 
nucleotide polymorphisms (SNP). SNP is a variation in a single 
nucleotide that occurs at a specific position in the genome, where 
each variation is present to some appreciable degree within a 
population. Such variations may fall within coding sequences of 
genes, non-coding regions of genes, or in the intergenic regions, and 
in this way they may influence the qualitative or quantitative 
characteristics of the mature proteins. SNPs in the DNA sequences of 
humans can affect how humans develop diseases and respond to 
pathogens, chemicals, drugs, vaccines, and other agents. SNPs are 
also critical for personalized medicine. 
Each year, millions of people take warfarin and other 
coumarins, which together form the group of oral anticoagulants. 
Although these vitamin K antagonists are remarkably effective at 
preventing cardioembolic stroke, myocardial infarction, and venous 
thrombosis, they double the incidence of hemorrhage. The 
hemorrhage risk is greatest during the first weeks to months of 
therapy. To reduce this risk, experts advocate prescribing the 
anticipated therapeutic dose to patients who are beginning warfarin, 
but until now there was no accurate way to estimate that dose. By 
using pharmacogenetics-based warfarin therapy, clinicians can now 
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estimate the therapeutic warfarin dose by genotyping their patients 
for single nucleotide polymorphisms that affect warfarin metabolism 
or sensitivity. The objective of pharmacogenetics-based coumarin 
therapy is to improve the safety and the effectiveness of 
anticoagulant therapy.  
The main place among the many genes that are related to the 
action and metabolism of oral anticoagulants takes vitamin K 
epoxide reductase complex subunit 1 (VKORC1), which is the 
molecular target of coumarin-based anticoagulants. VKORC1 is a 
key enzyme in recycling reduced vitamin K, plays an essential role in 
post-translational modification and activation of vitamin K-
dependent coagulation factors. Since the cloning of VKORC1 in 
2004, frequent VKORC1 single nucleotide polymorphisms and 
haplotypes have been consistently associated with warfarin dose 
required to therapeutic anticoagulation. Specifically, 5 SNPs define 2 
major haplotypes in Europeans rs719616114 (T381C); rs9923231 
(G-1639A); rs9934438 (C1173T); rs8050894 (G1542C) and 
rs2359612 (C 2255T). Haplotype A carrying the minor alleles was 
associated with lower mRNA expression and lower warfarin 
maintenance dose, compared with the major allele haplotype B. The 
mean therapeutic doses of warfarin per day differed significantly 
based on SNPs (and its corresponding haplotype): 2.7-3.4 mg for 
haplotype A/A, 4.3-4.9 mg for genotype haplotype A/B, and 6.0-6.2 
day for haplotype B/B. 
Thus, the introduction of the determination of single 
nucleotide polymorphism of vitamin K epoxide reductase complex 
subunit 1 by polymerase chain reaction into the routine practice will 
optimize the selection of a dose of oral anticoagulants for patients 
who need it, and will significantly increase the effectiveness of 
treatment and reduce the risk of bleeding complications. 
 
 
 
 
 
 
